Edit

Ligand

http://www.ligand.com/

Last activity: 13.07.2026

Active

Categories: BioTechBusinessCorporateDevelopmentDrugIndustryMedtechProductProviderTechnology

The official Twitter channel for Ligand Pharmaceuticals Incorporated. Please read our Twitter Guidelines at: https://bit.ly/2JLXwmh

Mentions

Location: United States, Kansas, Lenexa

Employees: 501-1000

Founded date: 1987

Twitter

Angel List

Investors 2

Date	Name	Website
-	InterWest ...	interwest....
-	Signet Hea...	signetheal...

Mentions in press and media 22

Date	Title	Description
13.07.2026	Agenus Announces Up To $340 Million Private Placement To Advance ROBBIN Trial	Agenus announced that it entered into a securities purchase agreement for an oversubscribed private placement of approximately $85 million in upfront gross proceeds and up to an additional $255 million if purchase warrants are fully exercis...
17.10.2024	invIOs Secures €8.2 Million to Propel Cancer Therapies Forward	In the world of biotechnology, funding is the lifeblood that keeps innovation alive. On October 15, 2024, invIOs GmbH, a Vienna-based biotech firm, announced a significant boost to its ambitions in cancer treatment. The company raised €8.2 ...
15.10.2024	invIOs Raises €8.2M in Series A Funding	invIOs GmbH, a Vienna, Austria-based biotechnology company developing novel therapies for cancer, raised €8.2m in Series A funding. Backers included existing shareholders and Ligand Pharmaceuticals, which recently acquired APEIRON, the form...
08.07.2024	Ligand to Acquire Apeiron Biologics, for $100M	Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-b...
24.06.2021	Vertex Pharmaceuticals Incorporated announces an Equity Buyback for $1,500 million worth of its shares.	Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces a share repurchase program. Under the program, the company will repurchase up to $1,500 million worth of its shares. The program is valid till December 31, 2022.
02.06.2021	GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement	NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered ...
24.07.2019	Ligand Pharmaceuticals Acquires Ab Initio Biotherapeutics, for $12M	Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) acquired Ab Initio Biotherapeutics, an antigen-discovery company based in South San Francisco, California, for $12m. Ab Initio brings to Ligand patented antigen technology that is synergist...
18.12.2018	Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals	Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for debilitating genetic diseases with no appro...
09.08.2018	Ligand to Acquire Drug Discovery Company Vernalis, For $43M	Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), a San Diego, CA-based biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, is to acquire Vernalis pl...
17.04.2015	Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team?	Evans, Metacrine’s founder, is a lauded gene expression researcher at the Salk Institute who has a number of successful (cancer and hormone-related) biotechs under his belt. Evans is known, according to his Salk profile, for his seminal hor...
22.05.2014	In California biotech deal, startup Viking Therapeutics snags 5 programs, $2.5M	Its lead candidate is an oral inhibitor of the enzyme FBPase, which plays an important role in how the body synthesizes glucose. According to Viking, the small-molecule drug has demonstrated safety and tolerability in early clinical trials ...
16.04.2012	Alzheimer’s researchers form company, look to clinical trial of cancer drug	ReXceptor is looking to raise funding for a phase 1 clinical trial and will eventually need to contract with a strategic partner to push the drug through lengthy and expensive clinical trials with Alzheimer’s patients, CEO Michael Haag told...
09.02.2012	CWRU researchers: Drug shows promise in reducing Alzheimer’s plaque in brain	Case touted the research as “a dramatic breakthrough in [the] effort to find a cure for Alzheimer’s disease,” but it’s important to note that research won’t mean anything for people suffering from Alzheimer’s until the results are replicate...
12.08.2011	Beyond EPO injections: Anemia treatment that comes in a pill	The anemia market could be worth up to $10 billion annually. It’s dominated by injectable biologic drugs, such as Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, with Amgen holding most of the market. Those drugs generally w...
29.06.2011	Ligand Pharmaceuticals Gets $10M In Credit Facility	San Diego-based Ligand Pharmaceuticals, a biopharmaceuticals firm, has raised $10M in a credit facility from Square 1 Bank. Square 1 said the $10M included an initial $5M in credit secured in March, which was increased by another $5M in Apr...
28.02.2011	GSK orphan drug gets full FDA approval to treat rare blood disorder	Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal...
-	Stealth San Diego startup Metacrine raising $33M. Are we reassembling the Seragon team?	An interesting new San Diego biotech – Metacrine – is in the works. CFO Trisha Millican said the company’s raised $6.85 million, and is aiming for $33 million – but otherwise is keeping silent on its dealings. So time for some extrapolation...
-	GSK orphan drug gets full FDA approval to treat rare blood disorder	GlaxoSmithKline has full approval on a drug that can boost platelet counts in patients who bleed and bruise easily due to a rare blood disorder. GSK (NYSE:GSK) drug Promacta has been developed to treat chronic idiopathic thrombocytopenic pu...
-	In California biotech deal, startup Viking Therapeutics snags 5 programs, $2.5M	A San Diego biotech startup focused on treating metabolic and endocrine disorders has picked up a portfolio of drug candidates and a $2.5 million investment from Ligand Pharmaceuticals (NASDAQ:LGND). Viking Therapeutics said it’s licensed f...
-	CWRU researchers: Drug shows promise in reducing Alzheimer’s plaque in brain	A drug that’s already approved by the FDA has shown promise in clearing away a plaque in the brain that’s associated with Alzheimer’s disease, Case Western Reserve University researchers have found. The drug, bexarotene (brand name Targreti...
-	Beyond EPO injections: Anemia treatment that comes in a pill	The pharmaceutical company Affymax just got $10 million for moving forward with an anemia treatment that would require one injection a month as opposed to as many as several shots a week. Imagine the opportunity if someone can take a simila...
-	Alzheimer’s researchers form company, look to clinical trial of cancer drug	Researchers from Case Western Reserve University made a big splash earlier this year when they published research that showed a skin cancer drug reversed Alzheimer’s disease in mice. Now, the researchers have formed a company, ReXceptor, to...

Ligand

Investors 2

Mentions in press and media 22

Reviews 0